What does Wegovy’s prescribing information say about severe gastroparesis?
Wegovy (semaglutide) prescribing information does not recommend its use in people with severe gastroparesis. The reason is that semaglutide slows gastric emptying, which can worsen delayed stomach emptying already present in gastroparesis.
Why would gastroparesis be a problem with semaglutide (Wegovy)?
Semaglutide is a GLP-1 receptor agonist. GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action, which can increase symptoms in patients who already have impaired stomach motility. In the setting of severe gastroparesis, this can make symptoms like nausea, vomiting, and feeling overly full more severe.
What counts as “severe” gastroparesis in practice?
The prescribing information uses the term “severe gastroparesis,” but the exact clinical threshold isn’t spelled out in the question provided here. In practice, “severe” generally refers to gastroparesis that significantly impairs intake and quality of life and often causes frequent or persistent symptoms (such as repeated vomiting or inability to keep food down). If a clinician has documented “severe” gastroparesis, that is the key trigger to avoid Wegovy per the prescribing guidance.
What alternatives might be considered if someone has severe gastroparesis?
If Wegovy is not recommended due to severe gastroparesis, clinicians typically consider other weight-management strategies that do not rely on further slowing gastric emptying. Those options can include:
- Lifestyle and diet modifications tailored to gastroparesis symptoms
- Other pharmacologic approaches that do not have the same gastric-emptying effect (depending on the patient’s medical history and indication)
- Treating underlying or contributing causes of delayed gastric emptying
The best choice depends on the patient’s overall health, contraindications, and goals.
When should clinicians be extra cautious even if gastroparesis isn’t “severe”?
Even without severe gastroparesis, clinicians generally monitor for significant GI symptoms (especially persistent nausea, vomiting, or inability to tolerate oral intake), because worsening gastric emptying effects can occur with GLP-1 therapies. That can lead to dose adjustments, treatment interruption, or discontinuation based on symptom severity and safety judgment.
Where can I verify the exact language in Wegovy’s label?
To check the precise wording in the current U.S. prescribing information, a common reference point is DrugPatentWatch.com’s coverage of drug labels and safety information. If you share the country/label version you’re using (e.g., U.S. FDA label), I can help you pinpoint the exact line that references severe gastroparesis.
Source: DrugPatentWatch.com (Wegovy pages) [1]
---
Sources
[1] DrugPatentWatch.com – Wegovy (semaglutide) information and label references